Literature DB >> 6794043

Hydrocortisone inhibits platelet prostaglandin and endothelial prostacyclin production.

K A Jørgensen, E Stoffersen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6794043     DOI: 10.1016/s0031-6989(81)80027-6

Source DB:  PubMed          Journal:  Pharmacol Res Commun        ISSN: 0031-6989


× No keyword cloud information.
  8 in total

1.  Inhaled budesonide regimen enhances serotonin- and arachidonic acid-induced platelet aggregation.

Authors:  L Hasselmark; R Malmgren; A Dumitrescu
Journal:  Agents Actions       Date:  1992-05

Review 2.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).

Authors:  William Stevenson; Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Reza Dana
Journal:  Ocul Surf       Date:  2012-01-25       Impact factor: 5.033

3.  Despite a massive increase in cortisol secretion in women during parturition, there is an equally massive increase in prostaglandin synthesis. A paradox?

Authors:  M L Casey; P C MacDonald; M D Mitchell
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

4.  Biphasic regulation by dexamethasone of IL-1- and LPS-stimulated endothelial prostacyclin production.

Authors:  G Prajgrod; A Danon
Journal:  Agents Actions       Date:  1992-03

5.  [Thrombotic thrombocytopenic purpura].

Authors:  C Aul; R E Scharf; T Königshausen; W Schneider
Journal:  Klin Wochenschr       Date:  1985-02-04

6.  Biphasic regulation by dexamethasone of IL-1- and LPS-stimulated endothelial prostacyclin production.

Authors:  G Prajgrod; A Danon
Journal:  Agents Actions       Date:  1992-05

7.  Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment.

Authors:  Ye Jin Ahn; Hyung Bin Hwang; Sung Kun Chung
Journal:  Korean J Ophthalmol       Date:  2014-03-14

8.  Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes.

Authors:  Belghmaidi Sarah; Hajji Ibtissam; Baali Mohammed; Soummane Hasna; Moutaouakil Abdeljalil
Journal:  J Ophthalmol       Date:  2016-08-17       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.